Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,505
Total Claims
$4.2M
Drug Cost
844
Beneficiaries
$4,996
Cost/Patient
Risk Score Breakdown 8/100
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+228%
Cost per patient vs peers
$4,996 vs $1,524 avg
+168%
Brand preference vs peers
36.6% vs 13.7% avg
Brand vs Generic
Brand: 3,473 claims · $4.0M
Generic: 6,018 claims · $183K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 660 | $724K |
| Sacubitril/Valsartan | 585 | $677K |
| Semaglutide | 512 | $641K |
| Empagliflozin | 287 | $360K |
| Apixaban | 265 | $298K |
| Dapagliflozin Propanediol | 165 | $211K |
| Empagliflozin/Metformin Hcl | 119 | $181K |
| Semaglutide | 87 | $148K |
| Inclisiran Sodium | 39 | $142K |
| Tirzepatide | 89 | $102K |
| Rivaroxaban | 63 | $95K |
| Empagliflozin/Metformin Hcl | 69 | $81K |
| Finerenone | 24 | $39K |
| Ticagrelor | 39 | $32K |
| Alirocumab | 48 | $31K |
Prescribing Profile
Patient Profile
73
Avg Age
60%
Female
2.23
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data